Redhill Biopharma Ltd. (NASDAQ:RDHL) is set to issue its quarterly earnings data before the market opens on Monday, November 13th. Analysts expect the company to announce earnings of ($0.72) per share for the quarter.
Redhill Biopharma Ltd. (NASDAQ RDHL) opened at $5.35 on Friday. Redhill Biopharma Ltd. has a 12 month low of $5.17 and a 12 month high of $12.23.
WARNING: “Redhill Biopharma Ltd. (RDHL) Scheduled to Post Quarterly Earnings on Monday” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/12/redhill-biopharma-ltd-rdhl-scheduled-to-post-quarterly-earnings-on-monday.html.
RDHL has been the topic of several research reports. HC Wainwright set a $33.00 price objective on shares of Redhill Biopharma and gave the company a “buy” rating in a research note on Wednesday, July 26th. Zacks Investment Research lowered shares of Redhill Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, July 29th. Roth Capital set a $27.00 target price on shares of Redhill Biopharma and gave the stock a “buy” rating in a research report on Monday, July 31st. UBS AG assumed coverage on shares of Redhill Biopharma in a research report on Wednesday, September 13th. They issued a “reduce” rating for the company. Finally, Seaport Global Securities assumed coverage on shares of Redhill Biopharma in a research report on Friday, October 6th. They issued a “buy” rating and a $19.00 target price for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $23.35.
Redhill Biopharma Company Profile
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.